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(iii) the evolution of worldwide competitive markets for the 
production and consumption of goods and services. Project 
success aspects included achieving client satisfaction and 
achieving business objectives, which mean the agreed ser­
vice levels. The key project management responsibilities 
include managing the triple constraints for projects – cost, 
time, and scope.  According to Chen and Huang (2013), 
completeness of requirements may contribute significantly 
to the success of building projects in terms of schedule 
success, cost success, quality performance and overall be­
nefit. Over the last two decades, research on project mana­
gement (Tishler et al. 1996; Tukel, Rom 1998; Roger 1999; 
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Introduction
Usually any project ends up with either success or failure in 
achieving all the objectives in a satisfactory way. According 
to Papke­Shields et al. (2010), project management evolved 
over the past two decades as both researchers and practitio­
ners have attempted to identify the causes of project failure 
and the various factors that lead to success. Meredith and 
Mantel (2012) reported that there are three major forces 
involved for the development of new methods in project 
management – (i) the exponential expansion of human 
knowledge; (ii) the growing demand for a broad range of 
complex, sophisticated customized goods and services; and 
Hammer, Champy 2003; Zhang et al. 2003; Evans 2005; 
Ward 2014; Mejillano et al. 2007) demonstrated that most 
of the projects fail either in meeting time and budget goals 
or in satisfying customer and/or company expectations. 
According to Tukel and Rom (1998), completion of a pro­
ject by scheduled due date was treated as one of the most 
frequently used measurements of project success. Time 
delays will be so severe that they can reap up in any task/
activity/phase of a project and reinforce in the connected 
stages. Hence considerable attention is needed for their 
control and this is becoming one of the big challenges for 
project people. This study focuses on time delays in pro­
jects.
Since health needs have top most importance in human 
society, both public and private pharmaceutical companies 
have taken up the challenge of providing affordable medici­
nes to more people around the world at lower costs. Despite 
aggressive application of good tools, methods and techniqu­
es, many pharmaceutical companies have been struggling 
to make their projects more economical and schedule­
oriented to achieve maximum service levels. Most of the 
major and big pharmaceutical companies are committed 
to provide affordable and innovative medicines by focusing 
on customer requirements and delivering the products at 
right time. Currently, these companies have been aggres­
sively using project management techniques to complete 
the projects in time and within budget and maintain their 
competitive advantage by meeting the market demands. 
The very nature of drug development cycle or product de­
velopment through its different stages and the competition 
prevailing amongst the pharmaceutical companies by en­
suring an early product launch to capture the market are 
just a few reasons for the growing importance of project 
management in pharmaceutical industry. 
The pharmaceutical industry is unique in its procedures 
and methods of manufacture since the integrity of its pro­
ducts must be ensured by three main functions – current 
good manufacturing practices, quality assurance, and qua­
lity control (Cole 1998). According to Hwang et al. (2008), 
pharmaceutical projects often demand a tailored benchmar­
king approach because of their intensive qualification and 
validation procedures. They developed and validated a ben­
chmarking framework for pharmaceutical capital projects 
by taking into consideration three major drivers – schedule, 
cost and dimensional performance. In pharmaceutical in­
dustry, competitive advantage and increased sales revenue 
would be achieved by reduced time­to­market (Nalewaik 
2005). In the management of pharmaceutical projects, the­
re has been a growing interest in finding ways and means 
to control delays in making drugs and taking to market 
in time. For example, Yang and Yau (2013) developed a 
computer­based method that integrates two process­ba­
sed schedule delay analysis methods simultaneously based 
on information flow analysis. The present study took the 
support of statistical factor analysis and applied both explo­
ratoratory and confirmatory factor analyses on the collected 
data to analyse time delays in pharmaceutical projects.
Statistical factor analysis is a multivariate statistical met­
hod used to identify common underlying variables called 
factors within a larger set of measures. There are two statis­
tical approaches, namely, exploratory factor analysis (EFA) 
and confirmatory factor analysis (CFA) that are used to 
examine the internal reliability of a measure.  EFA is helpful 
in the initial stages of analysis to explore interrelationships 
among sets of variables and reduce them to a few factors 
so as to arrive to a measurement model. CFA is used in the 
later part of analysis to test the model derived from EFA, 
by testing its “goodness of fit” and conformity of the fac­
tors.  Several researchers applied statistical factor analysis 
to several fields including project management for analysis 
of data collected on different issues. Bryson and Bromiley 
(1993) used factor analysis to identify major factors from 
various variables describing the context of the projects, their 
planning and implementation processes and project outco­
mes. They reported that a number of contextual variables 
strongly influence project planning and implementation 
process, and indirectly influence the outcomes through 
planning and implementation process.   They added that 
both process and contextual variables affect project outco­
mes directly.  Shi and Wright (2001) used both exploratory 
and confirmatory factor analyses to examine and valida­
te factor structures of international business negotiator’s 
profile. They used the commonly accepted goodness­of­fit 
indices as reported by Jöreskog and Sörbom (1993) to assess 
the overall fit of the measurement model.  Sureshchandar 
et al. (2002) identified the critical factors of service quality 
from the customer perspective, developed an instrument to 
measure customer­perceived service quality based on those 
factors and with the help of CFA, they empirically tested 
and validated the instrument. Wang and Ahmed (2004) 
developed an organizational innovativeness construct and 
assessed its validity and reliability using confirmatory factor 
analysis.   This study, after identifying the prominent factors 
that delay the pharmaceutical projects from EFA, attemp­
ted to test the “goodness of fit” of the model and validate it 
further using CFA.
Chan and Tam (2000) examined the underlying factors 
affecting the quality of building project and found that pro­
ject management action by the project team was the most 
powerful predictor of client’s satisfaction with quality.  Li 
et al. (2005) investigated into the relative importance of 
various potential critical success factors for construction 
projects in UK with public­private partnerships (PPPs) and 
private finance initiative (PFI) and identified the three most 
important factors out of them. Doloi (2009) applied factor 
analysis to identify the prominent factors that influence 
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contractors’ performance in construction projects.  Aubry 
et al. (2010) made a survey on transitions of project mana­
gement offices (PMOs), which are dynamic organizational 
entities and found that the transition of a PMO from one 
configuration to the next is not a question of being right or 
wrong. Nwachukwu and Emoh (2010) analysed materials 
as an integral part of direct and indirect factors that hinder 
project management success of public and private sector 
construction in Nigeria. They used factor analysis to derive 
potential factors. Jou et al. (2010) used factor analysis to 
identify the key elements that affect new product develo­
pment (NPD) in a semiconductor equipment manufactu­
ring firm, whereas Thomas and Vilakshan (2011) used for 
software project risk management.  Much of the literature 
concerned with projects in various fields except pharma­
ceutical industry. Hence this study attempted to examine 
and validate important time­delay factors in pharmaceuti­
cal projects and as a first step the study focused on product 
based projects only.  
The objective of this work is to come out with a fra­
mework to control time delays in pharmaceutical product 
projects in order to help the project people to meet the plan­
ned service levels. It has been attempted to analyse in depth 
the various issues that contribute to time delays. By perfor­
ming surveys in pharmaceutical companies and interacting 
with experienced project people, the study explored several 
issues that hamper achievement of service levels in terms of 
time in pharmaceutical projects. To derive the major factors 
from the feedback data, exploratory factor analysis was used 
and to validate the constructs thus derived, confirmatory 
factor analysis was used. Taking the results to the notice 
of experienced pharmaceutical project managers, valuable 
information on different remedies to control time delays 
was collected. Finally, a framework was developed to give 
an overall picture of time delays and remedial measures to 
control them in pharmaceutical projects.
1. Research methodology
Industries like pharmaceutical, bio­tech, life sciences and 
R&D are quality and schedule driven sectors marked by 
strong competition to launch their product first in the mar­
ket and capture high marginal profits for their survival and 
future growth.  In the light of treating reduced time­to­mar­
ket as one of the important factors to achieve competitive 
advantage and increased sales revenue in pharmaceutical 
projects (Nalewaik 2005), this study was initiated to exa­
mine the reasons behind not achieving service levels in 
pharmaceutical projects in terms of time dimension. 
To study the importance of time dimension in achieving 
the service levels of pharmaceutical projects, a simple ques­
tionnaire was distributed to managers at different levels dea­
ling with projects in four big pharmaceutical companies – A, 
B, C and D (to maintain confidentiality, the names of the 
companies are suppressed) in India. They were requested to 
express their perception on importance of time dimension 
in achieving the service levels of projects on a scale of 0–5, 
‘0’ representing ‘not important’ and the remaining scores 
representing importance of time proportionately with ‘5’ the 
highest importance.  A total of 137 managers responded and 
the weighted average was found to be around 3.5, with no 
one opting for zero importance. This result provided good 
support for the fact that time is an important dimension 
in the success of pharmaceutical projects. In continuation 
of this, another survey was taken up simultaneously in the 
companies to check the status of different projects during 
the financial year 2006–07 in terms of time.  Four categories 
of status of 91 projects were considered  – completed in time, 
completed with delays, work­in­progress projects as per 
schedule, and work­in­progress projects with delays. It was 
observed that about 70% of the projects were completed in 
time and remaining ones completed with delays in all the 
four quarters. Most of the work­in­progress projects were 
moving as per schedule in the first two quarters, and in the 
remaining two quarters, the percentage was coming down 
with more delays. 
The above two preliminary studies motivated the pre­
sent research work by establishing a strong base to proceed 
further for a detailed analysis of the reasons behind time 
delays and thereby finding remedies to mitigate them in 
improving the service levels of pharmaceutical projects. 
For this, a detailed survey was conducted in the four phar­
maceutical companies to collect useful feedback about the 
reasons behind time delays in the projects.
1.1. Survey instrument
As a first step, face­to­face interviews were conducted with 
several pharmaceutical project managers, who directly 
involved in managing the projects. This attempt led to 
preparation of a draft list of reasons behind success and 
failure of projects in terms of time. The list is further refi­
ned by interactions with a group of selected senior project 
managers having long experience with pharmaceutical 
projects. Based on these interactions, a final list consisting 
of a total of 13 reasons behind time delays in pharmaceu­
tical projects was prepared.  To get the feedback of people 
on the significance of each of these 13 reasons for time 
delays, a questionnaire was developed and circulated to 
different people who are working in those four companies 
and are all internal project stakeholders only.  They were 
requested to fill the questionnaire by assigning a signifi­
cance level to each reason on a Likert scale of 1–5, which 
ranges from ‘not at all significant’ (assigning a score of 1) 
to ‘most significant’ (score of 5) and the remaining ones 
representing the relative significance. All the reasons are 
listed in Table 1 and the questionnaire is given in Table 
AI of Appendix.
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To analyse the feedback data, statistical factor analysis, 
both exploratory and confirmatory, has been used.  For 
exploratory factor analysis of survey data, the method of 
principal component analysis is used along with Varimax 
rotation method to reduce the variables to a minimum 
number of factors. To check the adequacy of the sample, 
KMO and Bartlett tests are conducted. Based on eigenvalues 
and proper loadings of the variables, a finite set of factors 
has been selected. Using the feasible value of Cronbach’s α 
(alpha), the reliability of each factor is checked. The con­
formity of the factors thus extracted from factor analysis 
is further examined with the help of confirmatory factor 
analysis. Thus, both EFA and CFA are used to extract reliable 
and well validated factors from the feedback data collected 
on various reasons related to time delays in pharmaceutical 
projects.
1.2. Data collection
Out of a total of 170 questionnaires distributed, 150 emplo­
yees from the four big pharmaceutical companies respon­
ded with proper and clear feedback.  Hence the response 
rate was above 88%, which is reasonably very good. 17% 
of respondents were senior project managers, 11% project 
managers, 11% senior managers, 18% managers, 22% depu­
ty managers and remaining 21% were assistant managers. 
Regarding length of experience, 21% of the respondents 
had above 10 years, 26% had 6–10 years, 30% had 2–5 
years of experience, and remaining 23% had about 2 years 
of experience. Regarding company­wise responses, 24% 
contribution was from company A, 29% from B, 28 % from 
C and the remaining 19% of respondents from company D. 
All these demographic details are given in Table 2.
2. Data analysis
2.1. Factor extraction
Keiser­Meyer­Olkin (KMO) measure of sampling 
adequacy was found to be 0.593, which is very close to the 
required merging of 0.6 (Alhaji et al. 2011) and also mat­
ching the requirements reported by Hair et al. (1995) and 
Tabachnick and Fidell (2007). In addition, the Bartlett’s Test 
of Sphericity produced a χ2 (Chi­square) of 1937.934, degre­
es of freedom of 78 and a significance level of 0.000, which 
is less than 0.05. These results indicate the significance of 
the sample. Using the latent root (eigenvalue) criterion, five 
factors were identified with eigenvalues greater than 1.0. It 
is found that all the five factors altogether account for about 
83.8% of the total variance, with first factor (F1) of 22.6%, 
second factor (F2) 21.8%, third factor (F3) 15.8%, fourth 
factor (F4) 13.8 % and fifth factor (F5) of 9.8% of variance. 
After rotating of the factors by Varimax method, the degree 
of association (correlation) of each variable with each factor 
was identified. A cut­off for all loadings followed here was 
Table 1. List of variables considered for statistical factor ana­
lysis on time delays
Item 
Number Reason for Time delay
1 Improper Planning (IP)
2 Improper Schedules (IS)
3 Wrong selection of Consultants (WC)
4 Improper Resource mapping (IR)
5 Improper Designs (ID)
6 Non­availability of Skilled Labour (NSL)
7 Improper Vendor Selection (IVS)
8 Improper Service Contracts (ISC)
9 Project Scope creep (PSC)
10 Delays in Order processing (DOP)
11 Improper Follow­ups (IF)
12 Delays in drawing Approvals (DA)
13 Non­availability of funds (NF)
Table 2. Demographic data of respondents
Category Total number of respondents Percentage (%)
Designation­wise:
Senior Manager 
(Projects) 26 17
Project Manager 16 11
Senior manager 17 11
Manager 27 18
Deputy Manager 33 22
Assistant Manager 31 21
Age­wise:
<2 years 34 23
2–5 Years 45 30
6–10 Years 39 26
Above 10 Years 32 21
Company­wise:
A 36 24
B 43 29
C 42 28
D 29 19
above 0.40 (Conway, Huffcutt 2003; Mathur et al. 2007). 
Each of Factor 1 and Factor 2 has three variables, whereas 
Factor 3 and Factor 4 have two variables with significant 
loadings greater than 0.9. Factor 5 has 3 variables with loa­
dings of 0.646, 0.411 and 0.800 respectively.  
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2.2. Factor reliability
The internal consistency of a measuring instrument is es­
tablished by using a reliability coefficient, Cronbach’s α 
(Cronbach 1951). Nunnally (1988) considered Cronbach’s α 
value of 0.6 and 0.7 or above as the criteria to demonstrate 
internal consistency of new scales and established scales 
respectively. In the most reliable form, the coefficients 
should be as close to 1.00 as possible (Reinard 2006). In 
the present work, the Cronbach’s α was derived for each 
of the five factors as 0.977, 0.966, 0.974, 0.718 and 0.273. 
Table 3 lists the communalities and factor loadings of all 
the 13 reasons, whereas Table 4 gives the eigen values, per­
centage of variance explained and reliability in terms of 
Cronbach’s α of all the five factors extracted. 
It is found that the fifth factor (F5) attributed very low 
value for both percentage of variance explained (9.8%) and 
Cronbach’s α (0.273) and hence it cannot be treated as a pro­
minent and reliable factor. Therefore, the first four factors 
have been treated as significant factors, based on their rea­
sonably and relatively high values of percentage of variance 
explained and reliability. In addition, all these four factors 
attained a cumulative percentage of total variance explained 
as 75.76, implying a satisfactory degree of construct validity. 
In addition, these factors have variables loaded with higher 
values, greater than 0.9.  
Depending on the type of variables grouped under 
each of the four factors, proper naming has been done for 
them. Factor 1 is named as ‘Resource problems’, Factor 2 as 
‘Monitoring & Control problems’, Factor 3 as ‘Scheduling 
problems’ and finally Factor 4 is named as ‘Planning pro­
blems’.  The factor of resource problems has contribution 
from the issues of improper resource mapping, non­avai­
lability of skilled labour and delays in drawing approvals. 
Similarly, ‘Monitoring & Control problems’ has contribu­
tion from wrong selection of consultants, improper designs 
and improper follow­ups. Improper schedules and delays 
in order processing contribute to the factor of scheduling 
problems. Planning problems is loaded with the issues of 
improper planning and project scope creep.  Table 5 lists 
all the four named factors along with the associated time 
delay issues (variables).
2.3. Confirmatory factor analysis 
Exploratory factor analysis (EFA) is concerned with the 
question of how many factors are necessary to explain the 
relations among a set of indicators and with the estimation 
of the factor loadings, whereas confirmatory factor ana­
lysis (CFA) is concerned with parameter estimation and 
tests of hypotheses regarding, for example, the number of 
factors underlying the relations among a set of indicators 
(Pedhazur, Schmelkin 1991). CFA is a type of factor analysis 
conducted to test hypotheses or confirm theories about the 
factors one expects to find and it is a subtype of structural 
equation modeling (Vogt et al. 2008) and is the initial step 
of a complete test of a structural model (Hair et al. 2006). 
According to Schumacker and Lomax (2004), CFA is com­
monly used to confirm that the indicators sort themselves 
Table 3. Factor analysis for the reasons of time delays
Variable
Communalities Factor 
loadingInitial Extraction
 IP 1.000 0.832 0.905 (F3)
2. IS 1.000 0.967 0.982 (F2)
3. WC 1.000 0.950 0.971 (F2)
4. IR 1.000 0.957 0.975 (F1)
5. ID 1.000 0.927 0.951 (F2)
6. NSL 1.000 0.922 0.956 (F1)
7. IVS 1.000 0.538 0.646 (F5)
8. ISC 1.000 0.415 0.411 (F5)
9. PSC 1.000 0.844 0.907 (F3)
10. DOP 1.000 0.967 0.982 (F2)
11. IF 1.000 0.944 0.968 (F2)
12. DA 1.000 0.972 0.985 (F1)
13. NF 1.000 0.663 0.800 (F5)
Table 4. Eigen values, variance and reliability of factors extracted
Factor 
extracted Eigen value
Percentage 
of variance 
explained
Reliability, 
Cronbach’s α
F1 3.076 22.6 0.977
F2 2.865 21.8 0.966
F3 2.048 15.8 0.974
F4 1.816 13.8 0.718
F5 1.091 9.8 0.273
Table 5. Names of the factors and the time delay issues 
grouped 
Factor Variables grouped
F1: Resource 
problems
IR: Improper Resource mapping
NSL: Non­availability of Skilled  Labour
DA: Delays in drawing    
Approvals
F2: Monitoring & 
Control problems
WC: Wrong selection of Consultants
ID: Improper Designs
IF: Improper Follow­ups 
F3: Scheduling 
problems
IS: Improper Schedules
DOP: Delays in Order processing
F4: 
Planning 
problems
IP: Improper Planning
PSC: Project scope  creep
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into factors corresponding to how the research has linked 
the indicators to the latent variables. While analyzing the 
measurement for self­directed learning, Harvey et al. (2006) 
used CFA to check the reliability of the results of explo­
ratory factor analysis (EFA) and the responses in the case 
of students’ self­directed learning.  Since EFA resulted in 
a finite number of significant factors that are required to 
explain the inter­correlations among the measured varia­
bles, and CFA is more appropriate than EFA (Bentler 1995), 
the present study applied CFA to confirm the results of EFA. 
In CFA, a model is built based on a priori information 
about the data structure in the form of knowledge derived 
from previous studies with extensive data. The confirmatory 
factor models will be displayed as path diagrams, where 
squares represent the observed variables, ellipses represent 
latent concepts (constructs or factors) and circles represent 
any errors in correlating variables to the respective cons­
tructs. Single­headed arrows show the direction of assumed 
causal influence and the curved double­headed (bidirectio­
nal) arrows represent covariance between two latent varia­
bles, that is, correlation among the paired dimensions. Each 
indicator reflects (has a loading on) one factor only and the 
errors are said to be not correlated (Pedhazur, Schmelkin 
1991). Taking into account the four factors derived from 
EFA, the path diagram of time delays in pharmaceutical 
projects is developed as shown in the Figure 1.  In the path 
diagram, e1 to e10 represent the errors in correlating varia­
bles to the respective factors.
To support the results of EFA, there are several clas­
ses of model fit indexes in CFA and Marsh et al. (1996) 
recommended that individuals utilize a range of fit indices. 
These classes of fit indices include discrepancy functions 
(chi­square test, relative chi­square, and RMS); comparing 
the target model with the null model (CFI, NFI, TFI, and 
IFI); information theory goodness of fit measures (AIC, 
BCC, BIC and CAIC); and non­centrality fit measures 
(NCP).   According to Jaccard and Wan (1996), usage of 
indices from different classes would overcome the limita­
tions of each index. Various authors (Bentler, Bonett 1980; 
Hoelter 1983; Jöreskog, Sörbom 1993; Bollen 1989; Steiger 
1990; Browne, Cudeck 1993; Byrne 1994; Hu, Bentler 1999; 
Schumacker, Lomax 2004; etc.) proposed different fit indi­
ces and recommended the cutoff values to them to assess 
the acceptance of model.    
According to Child (2006), three common measures of 
overall goodness of fit are a chi­square (χ2) measure, go­
odness of fit index (GFI) and root mean square residual 
(RMR). Carmines and Zeller (1990) suggested the ratio of 
χ2 to df (degrees of freedom) of 2 or 3 as criterion of fit. This 
relative χ2 should be less than 2 or 3 (Kline 1998; Ullman 
2001). According to Hair et al. (2006), the recommended 
values for relative χ2 is 3.0 or below. In this study, the χ2 value 
is derived as 82.271 and df as 29 and hence the relative χ2 is 
found as 2.837, which is within the acceptable range as spe­
cified in the literature reports. RMR and GFI fall between 0 
and 1 with GFI to be as near to one as possible, whereas RMR 
as near to zero as possible (Child 2006). According to Byrne 
(1994) and Hair et al. (2006), GFI value should exceed 0.90, 
the adjusted goodness of fit index (AGFI) should be 0.8 or 
above (Hair et al. 2006) and Normed fit index (NFI) should 
be greater than 0.90 (Byrne 1994) or 0.95 (Hu, Bentler 1999; 
Schumacker, Lomax 2004) and both GFI and AGFI may 
range from 0 to 1 (Pedhazur, Schmelkin 1991). Cole (1987) 
stated that values greater than 0.9 and 0.8 for GFI and AGFI 
Fig. 1. Path diagram for confirmatory factor analysis of time delays 
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respectively, usually indicate good fit. In the present study, 
the derived values for RMR, GFI and AGFI are 0.047, 0.911 
and 0.832 respectively, which are all within the acceptable 
ranges. Hence overall goodness of fit has been established 
for the model.
The unidimensionality of the measure represents the 
existence of a single construct underlying a set of measures. 
According to Anderson and Gerbing (1991), the unidimen­
sionality of the measure is a highly mandatory condition 
for checking construct validity and reliability. According to 
Bollen (1989), a comparative fit index (CFI) value of 0.85 
represents progress and should be acceptable. CFI of 0.90 
or above represents strong evidence of unidimensionality 
for a model (Byrne 1994; Hair et al. 2006). In this study, the 
derived value for CFI is 0.972, which strongly supports the 
unidimensionality of the measurement model.  
Table 6 lists all the derived values of measures of goo­
dness of fit and unidimensionality and these results well 
confirm the goodness of model fit and validate the unidi­
mensionality of the model. Hence CFA provided significant 
support for the grouping of reasons behind time delays in 
pharmaceutical projects under the said four major factors.
Table 6. Model fit indexes for time delays
Model fit index Recommended value or cut­offs
Measurement 
model
Chi­square (χ2) to 
degree of freedom 
ratio (CMIN/df)
3.000 or below 2.837
Goodness of fit 
index (GFI) 0.900 or above 0.911
Adjusted goodness 
of fit index (AGFI)  0.800 or above 0.832
Root mean square 
residual (RMR)
Nearer to 0.0 or 
below 0.05 0.047
Comparative fit 
index (CFI) 0.900 or above 0.972
2.4. Interpreting results
All the extracted and validated factors are described below 
in the light of grouped reasons:
1. Resource Problems: In pharmaceutical projects, pe­
ople work for multiple projects at a time, and this 
situation leads to keeping same people on more than 
one project.  Such multi­tasking by single resource 
keeps lot of pressure on that resource. When suffici­
ent labour with skill set matching the requirements 
of projects is not available, many tasks will be kept 
pending and those completed tasks would have poor 
quality. In such case, rework by other skilled labour 
will be awaited leading to time delays. While doing 
detailed engineering in projects, external consult­
ants would send execution drawings for approvals 
of project team members who spread across many 
functional departments or divisions. The issues of 
multi­tasking, integration failure among the project 
team members, etc. lead to delays in approving the 
drawings. 
2. Monitoring & Control problems: Selection of low 
profile consultants due to cost cutting procedures 
and improper negotiations by project team needs 
lot of follow­ups to get the drawings, detailed Bill 
of Quantities (BOQ), etc. in time from the consul­
tants. When such follow­ups are absent, lot of time 
delays happen. And at the same time, improper de­
signs of equipment, for example selection of MOC 
(Material of construction), design parameters, etc. 
lead to time delays in projects. This is because of 
re­ordering with proper designs. Similarly, when 
important activities like delivery of long lead equi­
pment by the vendors, services from external agen­
cies, etc. are not properly tracked and controlled, 
the project or the concerned project tasks may be 
delayed.
3. Scheduling problems: When micro­level (individual) 
and macro­level (combined) activities are not pro­
perly scheduled according to the inter­connections 
and concurrence among different functional de­
partments, projects would face delays. Due to lot 
of procedural requirements in ordering process, 
like preparation of user requirement specifications 
(URS), collection of quotations from multiple ven­
dors, technical bid analysis (TBA) and final nego­
tiations, etc., the procurement cycle period would 
be enhanced and becomes a source of time delays.
4. Planning problems: Improper planning of manpo­
wer, equipment, resources, etc. in projects contri­
butes to time delays. In most of the pharmaceutical 
projects, continuous change requests from users 
would be common. They enhance the scope of the 
project further and further. Such scope creep would 
require additional time to accomplish all the added 
requirements. 
Another round of personal interactions and brain­stor­
ming exercise with experienced project managers and study 
of various projects in the four big Indian pharmaceutical 
companies helped to prepare a list of remedies to control 
time delays. These remedies stood as great support to design 
the framework to improve service levels. The remedies thus 
collected are discussed in the following sections.
3. Remedies to control time delays
Based on the derived factors and their loaded reasons that 
contribute to time delays, a list of remedies to control time 
delays was prepared with the help of personal interactions 
established with the experienced and senior project 
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managers working in the five big pharmaceutical compa­
nies. Figure 2 provides a framework that shows the contri­
butions and remedies to time delays in pharmaceutical 
projects and the following paras describe those remedies. 
 –  Blended resource approach: It is a pool of talented pe­
ople from different disciplines of projects working for 
multiple projects as per the individual project requi­
rement which will be useful for optimum utilization 
of resources.
 – Estimation and forecast of shortage: Estimation and 
forecast of skilled labour at regular intervals will be 
used to maintain required strength at any point of 
time and thereby avoiding any shortages of required 
skills and skilled labour.
 – Regular quality training: Regular quality training pro­
grammes in special areas improve the skill set of the 
people, who can show better performance in complex 
project activities.
 –  Common talent pool: Maintaining a pool of talented 
people across the organization, can be useful for de­
veloping the required resources on multiple projects 
wherever necessary.
 –  Co­ordination among departments: Consultants 
submit the project related drawings for approval of 
multiple departments, which have stake in the con­
cerned projects. In such cases, instead of individual 
study of the drawings by each department, it would 
be better to form a team among departments to study 
Fig. 2. Framework showing contributions and remedies for time delays in pharmaceutical projects
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and approve the drawing, by this way time delays will 
be reduced considerably.
 –  Single point of contact (SPOC): Instead of multiple 
people, one person from a project team may conti­
nuously coordinate with direct and in direct project 
stakeholders, this can help in maintaining and trac­
king projects to get things done quickly.
 –  Selection by track record: For selection of good con­
sultants to the project, it would be better to collect the 
feedback on consultants’ performance and their track 
record from project teams of other companies. This 
would help project teams in getting right drawings 
and required inputs from consultants at right time.
 – Tender system: Transparent and un­biased tender 
system would lead to selection of qualified consul­
tants for complex and mega project, right choice of 
qualified consultants benefits project teams from be­
ginning to end of the project by avoiding delays in 
getting right drawings approvals and right inputs at 
right time from the consultants.
 –  Standardization in design: Standardization of designs 
in projects will be useful to swap the equipment from 
one project to other and also reduce the inventory 
on spares.
 –  Application of competent tools: Use of proper compe­
tent tools helps project team to have proper design of 
equipment, right selection of material of construction 
(MOC), easy maintenance, user friendliness, adop­
tion of new technologies, improvisation in automa­
tion, etc.
 –  Use of trackers: Utilization of project trackers helps 
in identifying the critical activities like delivery de­
lays of equipment, resource requirements, etc. of the 
projects.
 –  Regular follow ups from the initial stage: Regular 
follow ups from the beginning of the project would 
help to minimize the problems faced at eleventh hour 
situations.
 – Micro level scheduling: A micro level schedule with 
sufficient details can be used as a predictive model of 
the project. Micro level schedules help project team 
members forecast project performance, facilitate qu­
ality decision making, shorten project feedback loops 
and accelerate team learning.
 – Control of over/under estimates: An inaccurate or 
superficial estimate of resources, time or budget 
may convince the project stake holders initially, but 
slowly throws challenges to project success; hence 
such inaccurate estimations should be avoided and 
controlled, as to have optimal schedule performance.
 –  Development and tracking of procurement plan: It 
would be better to have good procurement plan from 
p2p (procurement­to­pay) in projects, which helps 
to minimize delivery delays or failures for long­lead 
delivery equipment / materials.
 – Regular refinement of vendor list: Development of 
new list of alternative vendors at regular intervals 
leads to better control on cost at the time of bulk 
order of equipment or materials, and split of orders 
on multiple vendors to minimize the order delays.
 – Clarity on user requirements: During the planning 
stage itself, it is important to classify the key success 
factors that coincide with the user requirements. Col­
lection of entire requirements from all the end­users 
during planning phase helps to have better project 
planning to optimize the project time lines.
 – Efficient WBS: Detailed and efficient work breakdown 
structure (WBS) provides a structured view of va­
rious components of a project, which are planned in 
sequentially lower tiers of details.
 – Establishment of change management plan: A proper 
change management plan with a positive approach 
could be adopted by involving all the project stake 
holders and incorporating their needs thorough out 
the project life cycle. To avoid any project disputes, 
it is important to always seek approval of changes 
from users and communicate them to concerned 
team members in a timely manner. 
Conclusions
There are several factors that contribute to the success or 
failure of a project and every project will be evaluated on the 
basis of some important dimensions, including time, cost, 
and quality.  All these issues should be properly analysed 
and handled while managing the projects.  Like other in­
dustries, pharmaceutical industry realized the importance 
of project management to meet the agreed service levels and 
many big pharmaceutical companies have been aggressively 
adopting various project management methods, tools and 
techniques.  Meager research has been done in the direction 
of project management in pharmaceutical industry.  In 
order to fill the research gap in literature on pharmaceuti­
cal project management and to have an in­depth analysis 
of the reasons that delay the projects, this study took the 
help of statistical factor analysis including both exploratory 
and confirmatory factor analyses. Four big pharmaceutical 
companies in the Indian sub­continent were selected for 
survey and feedback data of the internal project people was 
collected. The measurement model based on the extraction 
of four reliable factors from the exploratory factor analy­
sis has been examined for its goodness of fit and further 
validation by confirmatory factor analysis. The results are 
quite satisfactory. The time­delay factors include resource, 
monitoring & control, scheduling and planning problems 
and each factor groups certain reasons. Interactions with 
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the senior project managers of pharmaceutical projects 
helped to collect useful information on various possible 
remedial measures to mitigate the time delays in projects. 
Based on the results of factor analysis and interaction with 
senior project people, a framework has been designed to 
control time delays in pharmaceutical projects. These fin­
dings provide valuable support to the pharmaceutical in­
dustry to control the time delays.  
This study focussed on time dimension in meeting the 
service levels of product­based pharmaceutical projects. 
In addition to time dimension, there will be many other 
dimensions that can further improve the service levels of 
pharmaceutical projects.  The data and information requi­
red for the present study was collected from four big phar­
maceutical companies in Indian sub­continent only. Future 
research would cover more number of big companies to 
improve the sample size and scope of analysis. In addition 
to product­based projects, other types of projects like capital 
projects in pharmaceutical industry would also be survey­
ed. Next, other dimensions like cost and client satisfaction 
would also be considered so as to enhance the analysis useful 
to improve the service levels of pharmaceutical projects.   
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APPENDIx
Table AI.  Survey questionnaire for statistical factor analysis of time delays
Name of the Employee:       
Company:
Designation:
Experience:
Reasons for TIME delays in pharmaceutical  projects
Significance level
Your suggestions to resolve the issue
1 2 3 4 5
1. Improper Planning
2. Improper Schedules
3. Wrong selection of Consultants
4. Improper resource mapping
5. Improper Designs
6. Non­availability of skilled labour
7. Improper Vendor Selection
8. Improper Service Contractors
9. Project Scope Creep
10. Delays in Order Processing
11. Improper Follow Ups
12. Delays in Drawing approvals
13. Non­availability of funds
Others, if any (your views)
14.
15.
Note: Please tick in the respective box to specify the significance level of each issue that affects TIME delays in pharmaceutical 
projects.  The values 1 to 5 mean ‘Least’ to ‘High’ significance in ascending order. 
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